CRISPR Therapeutics AG (CRSP) Stock Price & How to Invest

CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.

CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, a Nobel Prize laureate in Chemistry, alongside Shaun Foy and Rodger Novak. It went public on the Nasdaq in October 2016 and entered a landmark collaboration with Vertex Pharmaceuticals in 2015 that ultimately led to Casgevy's FDA approval in December 2023 for sickle cell disease and in January 2024 for transfusion-dependent beta-thalassemia. The company has been led since December 2017 by CEO and Chairman Samarth (Sam) Kulkarni, a former McKinsey partner with a PhD background who joined in 2015 as Chief Business Officer. Under his leadership the pipeline has expanded into next-generation allogeneic CAR-T programs (CTX112, CTX131), in vivo cardiovascular gene editing (CTX310, CTX320), and in May 2025 the company paid $95 million upfront to acquire CTX611, a clinical-stage siRNA therapy for thrombosis prevention.

Through 2026 the numbers have started to move, slowly. Revenue rose from about $1.5 million in Q1 2026 to about $10.2 million in Q2, and the Q2 net loss narrowed to about $91.2 million (EPS of -$0.94 against a -$1.18 consensus), the smallest quarterly loss in the past year. The company ended June 2026 with about $2.36 billion of cash against roughly $784 million of debt, the latter largely from the early-2026 convertible notes. The stock has not followed: it closed at $50.37 on October 16, 2026, down about 6% year to date and 26% over one year, and about 11% lower over the past month. Analyst views remain split, from UBS initiating at Neutral with a $52 target on October 15, 2026 to a mean target near $86 across 19 analysts. Third-quarter results are expected around November 9, 2026, with consensus near $16.6 million of revenue and EPS of -$1.06, and investor attention is also on upcoming CTX310 trial data.

The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. The convertible notes add about $784 million of debt that will eventually need to be repaid or converted, with dilution risk if conversion happens. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The share price, down about 26% over the past year, reflects meaningful skepticism about the pace of the commercial ramp, and binary clinical readouts such as CTX310 can move it sharply in either direction.

19 analysts publish price targets on CRSP, averaging $85.63 against a $49.25 price as of October 2026, or +73.9%. The published targets run from $44.00 to $291.00, a wide spread, and the ratings split 13 buy, 10 hold, 0 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CRSP forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on CRISPR Therapeutics AG. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. First-Mover Advantage in Commercial Gene Editing. Casgevy is the world's first approved CRISPR-based medicine, giving CRISPR Therapeutics a durable head start in manufacturing know-how, regulatory relationships, and patient community trust. The most optimistic published target, $291.00, assumes this works close to its best case.

The case against. The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $13.4 million over the twelve months to June 2026. The most pessimistic target, $44.00, is roughly what CRSP is worth if this bites instead.

Read the full bull and bear case on CRSP, including what would have to change to break either one. Walnut is not an investment adviser.

No. CRISPR Therapeutics AG (CRSP) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CRISPR Therapeutics AG's investor relations page or your broker.

• Revenue (TTM to Jun 30, 2026): ~$13.4 million (Q2 2026 ~$10.2 million)
• Revenue (Full Year 2025): ~$3.5 million
• Net loss (TTM): ~$451 million; Q2 2026 ~$91 million
• EPS (Q2 2026, actual vs estimate): -$0.94 vs -$1.18
• Market capitalization: ~$4.9 billion at $50.37 (Oct 16, 2026)
• Cash vs debt (Jun 30, 2026): ~$2.36 billion cash vs ~$784 million debt
• P/E ratio: Negative (not meaningful; forward EPS estimate ~-$3.55)
• Analyst mean price target: ~$85.63 (19 analysts)

Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $4.9 billion less roughly $1.6 billion of net cash leaves an enterprise value near $3.3 billion, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $86.

If you want CRSP exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses CRSP naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to CRSP: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CRSP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ARKG, ARKK), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CRSP sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CRSP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CRISPR Therapeutics is a commercial-stage gene-editing company whose entire near-term financial story hinges on the uptake trajectory of Casgevy, a one-time therapy priced at $2.2 million per patient. Reported revenue is still tiny (about $10.2 million in Q2 2026, $13.4 million over the trailing twelve months), though Q2 was the first quarter of visible acceleration. If you believe gene editing will become a mainstream treatment modality and that Casgevy's reimbursement coverage will expand meaningfully while CRSP's CAR-T and cardiovascular pipeline adds further option value, the question becomes sizing and overlap with other biotech positions, not timing. The risk is that the commercial ramp stalls due to the therapy's complexity, payer pushback, or manufacturing costs, leaving the company burning through its approximately $2.36 billion cash position faster than new revenue can replace it.

Whether CRSP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRSP a buy or a sell?, and where the stock could go from here in the CRSP stock forecast.

For income investors, whether CRSP pays a dividend and how the payout looks is covered in does CRSP pay a dividend? And to weigh CRSP against a peer, read the full side-by-side comparisons: CRSP vs VRTX and CRSP vs REGN.